skip to Main Content

Submitted Case

2024
1. Submitted Case
2. Submitted Case
3. Submitted Case
4. Submitted Case
5. Submitted Case
6. Submitted Case
7. Submitted Case
8. Submitted Case
9. Submitted Case
10. Submitted Case
11. Submitted Case
Patient Information: (Do not provide name of the patient)
Age
  73 M
Diagnosis
  Bladder cancer
Imaging
  Several PET CT scans – will pull up these and sim scan at time of discussion
Pathology
  Urothelial carcinoma
Stage
  Recurrent to LN
Overall Oncology Management Plan
Chemotherapy (if given, what is the regimen)
  • Initially found to have superficial bladder cancers s/p TURBT and intravesicular BCG, • with development of high grade muscle invasive bladder cancer in 2019 with LN involvement on imaging. • He received neoadjuvant cisplatin and gemcitabine followed by radical cystoprostatectomy with ileal conduit on 1/8/2020 at Stanford with complete pathologic response, pT0 N0 and with incidental finding of prostate adenocarcinoma, GS 3+3, pT2 N0. • He received Opdivo from 3/19/2021 – 4/5/2022. • He was found to have enlarging right iliac LN that was biopsied as metastatic urothelial carcinoma. • 11/28/2023 – 2/9/2024 Treated with enfortumab veodtin / Keytruda.
Radiation Therapy (fields, dose)
  Plan to treat pelvis (without cystectomy bed) and boost the LN – question about neobladder and pelvic dose as well as LN dose
Images
Session Name
  GU Specialist Dr. Ron Chen – May 20, 2024
Session ID
  13700
created_by
  7135
post_id
  13700
Back To Top